Tabbara N, Dioverti-Prono M, Jain T
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):116-125.
PMID: 39644015
PMC: 11706248.
DOI: 10.1182/hematology.2024000535.
McKinney C, Bigelow W, Venkat P, Shah N
ACG Case Rep J. 2024; 11(9):e01515.
PMID: 39267624
PMC: 11392473.
DOI: 10.14309/crj.0000000000001515.
An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W
Cancer Med. 2024; 13(12):e7372.
PMID: 38923216
PMC: 11196838.
DOI: 10.1002/cam4.7372.
Ou L, Su C, Liang L, Duan Q, Li Y, Zang H
Hum Vaccin Immunother. 2023; 19(3):2267865.
PMID: 37846106
PMC: 10583622.
DOI: 10.1080/21645515.2023.2267865.
Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M
Curr Oncol. 2023; 30(7):6330-6352.
PMID: 37504327
PMC: 10378049.
DOI: 10.3390/curroncol30070467.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, DSouza A
Br J Haematol. 2023; 203(5):736-746.
PMID: 37287117
PMC: 10700672.
DOI: 10.1111/bjh.18909.
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche J
Semin Hematol. 2023; 60(1):52-58.
PMID: 37080711
PMC: 10119490.
DOI: 10.1053/j.seminhematol.2023.02.003.
Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia.
Quattrone M, Di Pilla A, Pagano L, Fianchi L
Clin Exp Med. 2023; 23(6):1823-1833.
PMID: 36715833
PMC: 9885910.
DOI: 10.1007/s10238-023-01000-9.
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Perales M
Bone Marrow Transplant. 2022; 57(10):1477-1488.
PMID: 35840746
PMC: 9285870.
DOI: 10.1038/s41409-022-01756-w.
Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?.
Tang K, Nastoupil L
J Immunother Precis Oncol. 2022; 4(3):150-159.
PMID: 35663108
PMC: 9138439.
DOI: 10.36401/JIPO-21-2.
Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
Zu C, Xu Y, Wang Y, Zhang M, Zhao H, Fang X
Curr Oncol. 2022; 29(2):490-496.
PMID: 35200544
PMC: 8870699.
DOI: 10.3390/curroncol29020044.
Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.
Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M
Front Immunol. 2021; 12:751754.
PMID: 34691067
PMC: 8535441.
DOI: 10.3389/fimmu.2021.751754.
[The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].
Zhonghua Xue Ye Xue Za Zhi. 2021; 42(6):441-446.
PMID: 34384148
PMC: 8295609.
DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001.
Management of hepatotoxicity of chemotherapy and targeted agents.
Mudd T, Guddati A
Am J Cancer Res. 2021; 11(7):3461-3474.
PMID: 34354855
PMC: 8332851.
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Li P, Zhou L, Ye S, Zhang W, Wang J, Tang X
Front Immunol. 2021; 12:638678.
PMID: 34335561
PMC: 8320511.
DOI: 10.3389/fimmu.2021.638678.
CAR-based cell therapy: evaluation with bibliometrics and patent analysis.
Yuan Y, Fu Q, Zhang Y, Xu D, Wu Y, Qiu Q
Hum Vaccin Immunother. 2021; 17(11):4374-4382.
PMID: 34184975
PMC: 8827635.
DOI: 10.1080/21645515.2021.1947100.
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Wu Y, Huang H, Luo Y
Front Immunol. 2021; 11:610500.
PMID: 33613534
PMC: 7890023.
DOI: 10.3389/fimmu.2020.610500.
Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.
Leick M, Maus M, Frigault M
Mol Ther. 2020; 29(2):433-441.
PMID: 33130313
PMC: 7854294.
DOI: 10.1016/j.ymthe.2020.10.022.
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Diaz de Heredia C, Fortuny-Guasch C
Infection. 2020; 49(2):215-231.
PMID: 32979154
PMC: 7518951.
DOI: 10.1007/s15010-020-01521-5.
Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z
Hematol Oncol. 2020; 39(1):75-86.
PMID: 32949412
PMC: 7983916.
DOI: 10.1002/hon.2807.
